ReviewFrontiers in immunology2026
The evolution of vaccine strategies for colorectal cancer: from conventional approaches to the mRNA era.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, with current treatment modalities frequently limited by tumor heterogeneity and immune evasion. Vaccine-based immunotherapy, particularly that utilizing messenger RNA (mRNA) technology, represents a promising innovative strategy due to its rapid development cycle, generally manageable safety profile in the short term, and potential for personalization. This review examines the limitations of traditional cancer vaccine platforms and contrasts them with the advantages offered by mRNA-based vaccines. It expounds on the various mechanisms through which mRNA vaccines target CRC, such as encoding tumor-associated antigens or tumor-specific neoantigens, delivering immune-stimulating cytokines, and modulating the immunosuppressive tumor microenvironment. An overview of recent clinical trials in the field of mRNA immunotherapy for colorectal cancer is provided. Preliminary evidence from early clinical studies indicates that these approaches exhibit a manageable safety profile and show signs of antitumor activity, showcasing significant potential for clinical application. Furthermore, we also discuss the challenges and prospects that mRNA vaccines are currently facing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.